Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM.

J Exp Med. 2013 May 6;210(5):951-68. doi: 10.1084/jem.20120950. Epub 2013 Apr 22. Erratum in: J Exp Med. 2017 Jan 19;:. J Exp Med. 2017 May 1;214(5):1557.

2.

MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.

Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, Karimipoor M, Soleimani M.

Tumour Biol. 2016 Jul;37(7):8993-9000. doi: 10.1007/s13277-015-4513-9. Epub 2016 Jan 12.

PMID:
26758430
3.

Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth.

Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, Zeng YX, Shao JY.

Breast Cancer Res. 2011 Jan 10;13(1):R2. doi: 10.1186/bcr2803.

4.

Regulation of nucleolin expression by miR-194, miR-206, and HuR.

Bose S, Tholanikunnel TE, Reuben A, Tholanikunnel BG, Spicer EK.

Mol Cell Biochem. 2016 Jun;417(1-2):141-53. doi: 10.1007/s11010-016-2721-2. Epub 2016 May 25.

PMID:
27221739
5.

Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells.

Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S, Luo D.

BMC Cancer. 2012 Jan 20;12:29. doi: 10.1186/1471-2407-12-29.

6.

miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1.

Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ, Yun JP.

Carcinogenesis. 2014 Feb;35(2):469-78. doi: 10.1093/carcin/bgt330. Epub 2013 Oct 1.

PMID:
24085799
7.

A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.

Kong LM, Liao CG, Zhang Y, Xu J, Li Y, Huang W, Zhang Y, Bian H, Chen ZN.

Cancer Res. 2014 Jul 15;74(14):3764-78. doi: 10.1158/0008-5472.CAN-13-3555. Epub 2014 Jun 6.

9.

Human anti-nucleolin recombinant immunoagent for cancer therapy.

Palmieri D, Richmond T, Piovan C, Sheetz T, Zanesi N, Troise F, James C, Wernicke D, Nyei F, Gordon TJ, Consiglio J, Salvatore F, Coppola V, Pichiorri F, De Lorenzo C, Croce CM.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9418-23. doi: 10.1073/pnas.1507087112. Epub 2015 Jul 13.

10.

Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.

Hannafon BN, Sebastiani P, de las Morenas A, Lu J, Rosenberg CL.

Breast Cancer Res. 2011 Mar 4;13(2):R24. doi: 10.1186/bcr2839.

11.

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.

Png KJ, Halberg N, Yoshida M, Tavazoie SF.

Nature. 2011 Dec 14;481(7380):190-4. doi: 10.1038/nature10661.

PMID:
22170610
12.

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.

Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA.

Breast Cancer Res. 2015 Jan 30;17:13. doi: 10.1186/s13058-015-0515-1.

13.

Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation.

Elgamal OA, Park JK, Gusev Y, Azevedo-Pouly AC, Jiang J, Roopra A, Schmittgen TD.

PLoS One. 2013 Oct 2;8(10):e76402. doi: 10.1371/journal.pone.0076402. eCollection 2013.

14.

miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3.

Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, Han S, Nie Y, Chen X, Zhao Q, Ding J, Wu K, Daiming F.

Mol Cancer Res. 2011 Jul;9(7):824-33. doi: 10.1158/1541-7786.MCR-10-0529. Epub 2011 May 31.

15.

MiR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1.

Zhang ZG, Chen WX, Wu YH, Liang HF, Zhang BX.

Biochem Biophys Res Commun. 2014 Nov 7;454(1):109-14. doi: 10.1016/j.bbrc.2014.10.049. Epub 2014 Oct 17.

PMID:
25450365
16.

Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.

Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, Tekmal RR, Vadlamudi RK.

Oncogene. 2014 Jul 10;33(28):3707-16. doi: 10.1038/onc.2013.332. Epub 2013 Aug 26.

17.

MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer.

Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, Wu J, Shen ZZ, Song HY, Shao ZM.

Clin Cancer Res. 2013 Mar 15;19(6):1389-99. doi: 10.1158/1078-0432.CCR-12-1959. Epub 2013 Jan 22.

18.

miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells.

Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, Yang PC, Chen HW.

Breast Cancer Res. 2011;13(6):R116. doi: 10.1186/bcr3059. Epub 2011 Nov 23.

19.

MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.

Hu Y, Zhu Q, Tang L.

PLoS One. 2014 Mar 17;9(3):e92099. doi: 10.1371/journal.pone.0092099. eCollection 2014.

20.

MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.

Ward A, Shukla K, Balwierz A, Soons Z, K├Ânig R, Sahin O, Wiemann S.

J Pathol. 2014 Aug;233(4):368-79. doi: 10.1002/path.4363. Epub 2014 Jun 2.

Supplemental Content

Support Center